FDA proposes to refuse Intarcia’s exenatide combo product NDA —again
Regulatory NewsJeff Craven
Clinical TrialsCombination products/companion diagnosticsHealth Authority meeting and communication strategyMedical DevicesNorth AmericaPharmaceuticalsRegulatory NewsJeff CravenClinical TrialsCombination products/companion diagnosticsHealth Authority meeting and communication strategyMedical DevicesNorth AmericaPharmaceuticals